FDA Clearance Tracker · P210011
xT CDx
Last checked: Nov 20, 2026Latest source record: Apr 28, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Apr 28, 2023
Approved
Time to decision
766 days
Received Mar 23, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P210011
- Device name
- xT CDx
- Applicant
- Tempus AI, Inc.
- Applicant location
- Chicago, IL
- Received
- Mar 23, 2021
- Decided
- Apr 28, 2023
- Decision
- Approved
- Supplements
- 5 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the xT CDx. The device is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling.Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PQP. The earliest in FDA's data is P160018, decided Dec 19, 2016.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Tempus AI, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Tempus ECG-MR510(k)
K254297 · Decided Sep 25, 2026 · 268 days after receipt
Device type: Atrial Fibrillation Risk Prediction Machine Learning-Based Notification Software (SBQ) · Cardiology
- Tempus ECG-PH510(k)
K253699 · Decided Aug 21, 2026 · 270 days after receipt
Device type: Pulmonary Hypertension Machine Learning-Based Notification Software (SAT) · Cardiology
- xR IVD510(k)
K241868 · Decided Sep 19, 2025 · 449 days after receipt
Device type: Next Generation Sequencing Based Tumor Profiling Test (PZM) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.